

Business [Stockhead](#)

ASX healthcare stocks riding the point-




Lumos and Atomo are making waves in point-of-care testing. Pic: Getty Images

Point-of-care testing emerges as one of the most disruptive shifts in global diagnostics



But long before Covid-19 POC testing was already bringing medical diagnostics out of laboratories and into GP clinics, pharmacies and homes leading to faster results and treatment.

The value proposition in oversold WA gold stocks
With gold coming back to life, small gold developers look oversold. Here's why Garimpeiro sees value in WA juniors Rumble and Javelin.



delivered.

Stockhead

CLIA waiver opens growth path for Lumos

Catalyst Metals led the small-cap charge with record Plutonic gold output while Pursuit drilled into a major lithium brine target and Bounty surged on PEP11 appeal news.

[Lumos Diagnostics \(ASX:LDX\)](#) flagship rapid point-of-care finger blood test

FebriDx is designed to differentiate between viral and bacterial respiratory

infections.

My News Feed

[Read More](#)

The test aims to help reduce the inappropriate and unnecessary use of



greater confidence while the patient was still in the consulting room.



SA News



Business

Blood spilt as chair

FebriDx is a 10-minute, finger-stick point-of-care test that distinguishes bacterial from non-bacterial, typically viral, respiratory infections." Ward said.

Mayfair Hotel to be

transformed after \$75m sale

Digital air traffic

control towers not fit for WFF, says



"That means clinicians can make an informed antibiotic decision in the exam room rather than relying on overlapping symptoms."



Airservices boss



The test received US FDA 510(k) clearance in 2023, but Ward said the biggest

commercial milestone came earlier this year when it secured a [USFDA](#)

[Laboratory Improvement Amendments \(CLIA\) waiver.](#)

Good Morning George Recommended based on what you've read



Business



UPDATED Animals



Tasmania

Ward said FebriDx was the only CLIA-waived, instrument-free point-of-care

test in the US that differentiated bacterial from non-bacterial respiratory infections across the full spectrum of respiratory illnesses rather than targeting a single virus.



"It's not just another rapid test," he said.



"It's positioned to change how frontline clinicians manage the estimated 80 million acute respiratory infection visits in the US each year by bringing more appropriate antibiotic prescribing into the point-of-care workflow."

Trending now **Read More**

"Reimbursement has been encouraging, with more than 90% of claims being paid, broad Medicare recognition and private payers typically reimbursing above Medicare rates."

above Medicare rates."

backlash

Commercial rollout is underway after Lumos signed a six-year exclusive national US distribution agreement worth ~US\$317 million with PHASE

Scientific

The housing affordability truth that should make every Aussie furious

PHASE has in turn established sub-distribution relationships with Schein, McKesson, NDC and others, representing more than 2,000 reps," Ward said.

A trip to McDonald's

"Our own and PHASE's field operation

care parent entities, which alone account for roughly half of all US care sites, while partners like Henry Schein and McKesson cover the rest of smaller practices.

New law creates WFH

"This is a capital efficient will benefit

the needle where volumes and

The Zendaya effect:

Inside star's huge year

Use of FebriDx is also being established within the WellStreet Urgent network

Future Falcons: U15 talents announce themselves at Barwon Showcase accounts," Ward said.

WellStreet is a good example of how we approach large urgent care

Aus spot for dope reason

"We started by piloting FebriDx at a single moderately complex WellStreet site in Fayetteville, Georgia, before CLIA waiver, to prove clinical value and refine how the test fits into the workflow," Ward said.

"After CLIA waiver, that pilot expanded to more than 40 sites and is now scaling across the broader WellStreet footprint in multiple states."

Ward said FebriDx now had the regulatory clearance, clinical evidence, economic rationale and commercial infrastructure to become a standard POC tool for managing acute respiratory infections.

Stockhead

The next respiratory season is about converting that foundation into visible, repeat utilisation and revenue across a growing base of high-value accounts."

Beyond FebriDx, Lumos is also involved in a range of POC development programs through commercial and technical collaborations.

Atomo grows supply partnerships and in-house tests

[Atomo Diagnostics \(ASX:AT1\)](#) powers part of the POC testing supply chain, but also develops and commercialises its own rapid diagnostic tests.

Its Pascal platform is used to make single-use test cassettes for rapid blood testing outside traditional laboratories.

The design is focused on improving ease of use, consistency and suitability for testing in clinics, pharmacies and other POC environments.

A key commercial relationship is its role as a supplier of these test cassettes to Lumos for their FebriDx test.

Atomo has an established presence in infectious disease testing, including HIV self-tests in markets such as Australia, New Zealand and the UK.

It has also developed a rapid syphilis test, targeting a sexually transmitted infection (STI) that has re-emerged as a growing public health concern in several developed markets, including Australia and the US, after years of decline.

The company also has early-stage programs in liver health testing. Atomo said recent new customers reflected growing interest in its test solutions as a scalable foundation for rapid diagnostic test development including self-testing at home.

Shift beyond POC testing to remote monitoring

While point-of-care testing continues to expand, [Adherium \(ASX:ADR\)](#) sits within a broader shift toward remote monitoring and decentralised healthcare.

Adherium's FDA-cleared Hailie Smartinhaler targets poor medication adherence in respiratory medicine, which is a key driver of avoidable flare-ups, hospitalisations and declining disease control.

Chief commercial officer John Perry told *Stockhead* the device attached to standard asthma and COPD inhalers, automatically recording when medication was taken and capturing real-world usage data between clinical visits.

"Most adherence programs fail because they depend on the patient adopting a new habit," he said.

"Ours does not because capture is passive, so the data keeps flowing even from the older, disengaged, hard-to-reach patients who need it most.

"On that foundation, care moves off patient recall and the occasional in-clinic snapshot and onto objective, real-world data captured between visits.

Perry said the data provided from the Hailie Smartinhaler was already changing clinical decisions.

"Clinicians see whether controller medication is actually being taken, whether reliever use is climbing and whether technique is the real problem," he said.

He said it then became a matter of "coach or prescribe" where care teams could tell whether the fix was a technique correction or a medication change.

And rather than adding another monitoring task for stretched clinicians, Adherium operates a managed care model where its team monitors adherence data, engages patients between appointments and escalates only clinically significant cases.

"Routine support is handled remotely, and only the patients who need clinical review reach the clinician," Perry said.

Adherium is also building a strong case for adoption, backed by clinical evidence from its iCARE program with Intermountain Health, based in Utah in the US, which has deployed 4,000 Hailie Smartinhalers across up to 2500 asthma and COPD patients in five healthcare facilities.

"Patients on Hailie-connected controllers used them as prescribed roughly two-thirds of the time, against the one-in-five typically reported in this population," Perry said.

"Nearly four in 10 cleared 80% adherence, the threshold associated with roughly half as many respiratory attacks."

The improvement translated into a 50.3% reduction in hospital admissions, a 20% reduction in emergency department visits and a 57% fall in annual cost of care per patient, from US\$36,837 to US\$15,899. Patient engagement remained high, with retention above 90% at 12 months.

Perry said moves to value-based care, where providers were paid for outcomes rather than activity, was driving a new commercial model well suited to Adherium.

"The iCARE cost-of-care reductions are exactly what health systems and payers now buy under value-based reimbursement," he said.

"So this is not a pivot away from revenue. It is the path to larger, stickier, outcomes-linked revenue, and to Adherium becoming a digital respiratory care partner rather than a connected device company."

This story does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

At Stockhead we tell it like it is. While Lumos Diagnostics is a Stockhead advertiser, the company did not sponsor this article.

Originally published as [ASX healthcare stocks riding the point-of-care testing wave](#)

Membership	About Us	Contact Us	Our New Network	Our Partners	Our Apps
Subscription packages	About us	Help & Support	Herald Sun	Buy Search Sell Classifieds	
Group/Corporate subscriptions	Meet the team	Story Tips	Daily Telegraph	Foxsports	
Geelong Advertiser App	Job Opportunities	FAQs	Courier Mail	Foxtel	
Today's Paper	Code of conduct	Standards of practice	The Advertiser	Hipages	
Newsletters	Subscription FAQs	Letter to the Editor	news.com.au	Kayo	
	Subscription terms	Licensing & Reprints	The Australian	My Tributes	
	Financial Hardship Policy	Advertise with us	The Mercury	Punters	
			The Cairns Post	odds.com.au	
			Gold Coast Bulletin	racenet.com.au	
			Townsville Bulletin	Sky News	
			The Chronicle	Coupons	
			NT News		
			The Weekly Times		
			CODE Sports		

A NOTE ABOUT RELEVANT CONTENT: We collect information about the content (including ads) you use across this site and use it to make both advertising and content more relevant to you on our network and other sites. Find out more about our policy and your choices, including how to opt-out of targeted advertising based on your browsing behaviour on our network. Sometimes our articles will try to help you find the right product at the right price. We may receive payment from third parties for publishing this content or when you make a purchase through the links on our sites.

[Privacy policy](#)

[Relevant ads opt-out](#)

[Cookie policy](#)

[Terms of use](#)